Vir Biotechnology, Inc. announced it will host a conference call at 4:30 p.m. ET on Wednesday, August 5 to discuss its financial results for the second quarter ended June 30, 2026. The call will also provide a corporate update, offering insights into the company's clinical-stage portfolio and ongoing programs. Investors can access the live broadcast through the Events & Presentations section of the Vir Biotechnology website.

Company Overview

Vir Biotechnology is a clinical-stage biopharmaceutical company focused on developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers targeting solid tumors. The company also maintains a preclinical portfolio across infectious diseases and oncologic malignancies.

Intellectual Property

Vir Biotechnology holds exclusive rights to the PRO-XTEN® masking platform for oncology and infectious disease applications. PRO-XTEN® is a registered trademark of Amunix Pharmaceuticals, Inc., a Sanofi company. The platform is integral to the company's therapeutic development strategy.

Contact Information

For media inquiries, Caren Scannell, Director of Communications, can be reached at cscannell@vir.bio . Investor relations questions should be directed to Kiki Patel, PharmD, Head of Investor Relations, at kpatel@vir.bio .

Morgan Stanley analyst Michelle Gilson has maintained an Overweight rating on Vir Biotechnology while raising the price target to $27 from $23. The revised target indicates a more optimistic outlook for the company's stock performance.

The rating upgrade comes as the firm reassesses Vir Biotechnology's market position and future potential. The increase in the price target suggests that the analyst expects significant upside from current levels.

Vir Biotechnology continues to be a key focus for investors in the biotechnology sector. The analyst's endorsement underscores confidence in the company's strategic direction and operational execution.